PortfoliosLab logoPortfoliosLab logo
HRMY vs. SUPV
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

HRMY vs. SUPV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Harmony Biosciences Holdings, Inc. (HRMY) and Grupo Supervielle S.A. (SUPV). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, HRMY achieves a -7.91% return, which is significantly lower than SUPV's -6.94% return.


HRMY

1D
-2.10%
1M
12.03%
YTD
-7.91%
6M
-14.93%
1Y
4.52%
3Y*
-1.66%
5Y*
1.50%
10Y*

SUPV

1D
1.01%
1M
39.42%
YTD
-6.94%
6M
-0.36%
1Y
-3.17%
3Y*
63.15%
5Y*
38.77%
10Y*
0.23%
*Multi-year figures are annualized to reflect compound growth (CAGR)

HRMY vs. SUPV - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
HRMY
Harmony Biosciences Holdings, Inc.
-7.91%8.75%6.53%-41.38%29.22%17.95%-9.60%
SUPV
Grupo Supervielle S.A.
-6.94%-20.75%281.41%87.96%11.80%-6.59%-16.54%

Correlation

The correlation between HRMY and SUPV is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.06

Correlation (3Y)
Calculated over the trailing 3-year period

0.07

Correlation (5Y)
Calculated over the trailing 5-year period

0.13

Correlation (All Time)
Calculated using the full available price history since Aug 19, 2020

0.14

Fundamentals

Market Cap

HRMY:

$2.03B

SUPV:

$869.13M

EPS

HRMY:

$2.48

SUPV:

-ARS 72.13

PS Ratio

HRMY:

2.25

SUPV:

1.31

PB Ratio

HRMY:

2.22

SUPV:

1.14

Total Revenue (TTM)

HRMY:

$899.11M

SUPV:

ARS 1.02T

Gross Profit (TTM)

HRMY:

$688.25M

SUPV:

ARS 425.09B

EBITDA (TTM)

HRMY:

$221.74M

SUPV:

-ARS 9.21B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

HRMY vs. SUPV — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HRMY
HRMY Risk / Return Rank: 4444
Overall Rank
HRMY Sharpe Ratio Rank: 4646
Sharpe Ratio Rank
HRMY Sortino Ratio Rank: 4141
Sortino Ratio Rank
HRMY Omega Ratio Rank: 4343
Omega Ratio Rank
HRMY Calmar Ratio Rank: 4545
Calmar Ratio Rank
HRMY Martin Ratio Rank: 4444
Martin Ratio Rank

SUPV
SUPV Risk / Return Rank: 4141
Overall Rank
SUPV Sharpe Ratio Rank: 3939
Sharpe Ratio Rank
SUPV Sortino Ratio Rank: 4747
Sortino Ratio Rank
SUPV Omega Ratio Rank: 4545
Omega Ratio Rank
SUPV Calmar Ratio Rank: 3838
Calmar Ratio Rank
SUPV Martin Ratio Rank: 3737
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

HRMY vs. SUPV - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Harmony Biosciences Holdings, Inc. (HRMY) and Grupo Supervielle S.A. (SUPV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


HRMYSUPVDifference
Sharpe ratioReturn per unit of total volatility

+0.18

Sortino ratioReturn per unit of downside risk

-0.24

Omega ratioGain probability vs. loss probability

1.06

1.07

-0.01

Calmar ratioReturn relative to maximum drawdown

0.10

-0.15

+0.25

Martin ratioReturn relative to average drawdown

0.18

-0.32

+0.50

HRMY vs. SUPV - Sharpe Ratio Comparison

The current HRMY Sharpe Ratio is 0.08, which is higher than the SUPV Sharpe Ratio of -0.09. The chart below compares the historical Sharpe Ratios of HRMY and SUPV, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

HRMY vs. SUPV - Drawdown Comparison

The maximum HRMY drawdown since its inception was -68.48%, smaller than the maximum SUPV drawdown of -95.98%. Use the drawdown chart below to compare losses from any high point for HRMY and SUPV.


Loading charts...

Drawdown Indicators


HRMYSUPVDifference

Max Drawdown

Largest peak-to-trough decline

-68.48%

-95.98%

+27.50%

Max Drawdown (1Y)

Largest decline over 1 year

-34.49%

-59.91%

+25.42%

Max Drawdown (3Y)

Largest decline over 3 years

-50.81%

-75.20%

+24.39%

Max Drawdown (5Y)

Largest decline over 5 years

-68.48%

-75.20%

+6.72%

Max Drawdown (10Y)

Largest decline over 10 years

-95.98%

Current Drawdown

Current decline from peak

-43.42%

-63.26%

+19.84%

Average Drawdown

Average peak-to-trough decline

-35.27%

-66.96%

+31.69%

Ulcer Index

Depth and duration of drawdowns from previous peaks

18.73%

28.53%

-9.80%

Volatility

HRMY vs. SUPV - Volatility Comparison

The current volatility for Harmony Biosciences Holdings, Inc. (HRMY) is 11.05%, while Grupo Supervielle S.A. (SUPV) has a volatility of 23.01%. This indicates that HRMY experiences smaller price fluctuations and is considered to be less risky than SUPV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


HRMYSUPVDifference

Volatility (1M)

Calculated over the trailing 1-month period

11.05%

23.01%

-11.96%

Volatility (6M)

Calculated over the trailing 6-month period

30.44%

47.05%

-16.61%

Volatility (1Y)

Calculated over the trailing 1-year period

42.03%

95.72%

-53.69%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

50.13%

71.42%

-21.29%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

52.45%

72.39%

-19.94%

Dividends

HRMY vs. SUPV - Dividend Comparison

Neither HRMY nor SUPV has paid dividends to shareholders.


PositionTTM202520242023202220212020201920182017
HRMY
Harmony Biosciences Holdings, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
SUPV
Grupo Supervielle S.A.
0.00%1.71%1.12%0.00%0.71%1.36%1.79%2.03%1.32%0.30%

Financials

HRMY vs. SUPV - Financials Comparison

This section allows you to compare key financial metrics between Harmony Biosciences Holdings, Inc. and Grupo Supervielle S.A.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00B400.00B600.00B800.00B1.00T20222023202420252026
215.39M
387.59M
(HRMY) Total Revenue
(SUPV) Total Revenue
Please note, different currencies. HRMY values in USD, SUPV values in ARS

HRMY vs. SUPV - Profitability Comparison

The chart below illustrates the profitability comparison between Harmony Biosciences Holdings, Inc. and Grupo Supervielle S.A. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%30.0%40.0%50.0%60.0%70.0%80.0%20222023202420252026
79.3%
43.6%
Portfolio components
HRMY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported a gross profit of 170.88M and revenue of 215.39M. Therefore, the gross margin over that period was 79.3%.

SUPV - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Grupo Supervielle S.A. reported a gross profit of 169.00M and revenue of 387.59M. Therefore, the gross margin over that period was 43.6%.

HRMY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported an operating income of 37.29M and revenue of 215.39M, resulting in an operating margin of 17.3%.

SUPV - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Grupo Supervielle S.A. reported an operating income of -15.76M and revenue of 387.59M, resulting in an operating margin of -4.1%.

HRMY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported a net income of 32.49M and revenue of 215.39M, resulting in a net margin of 15.1%.

SUPV - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Grupo Supervielle S.A. reported a net income of -12.03M and revenue of 387.59M, resulting in a net margin of -3.1%.


Frequently Asked Questions


HRMY and SUPV have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

SUPV has higher volatility (23.01%) compared to HRMY (11.05%). In terms of maximum drawdown, HRMY dropped -68.48% vs SUPV's -95.98%.

HRMY currently has the higher Sharpe Ratio (0.08 vs -0.09), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for HRMY and SUPV

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer